QUARK BIOSCIENCES TAIWAN, INC.
302058 新竹縣竹北市新竹生醫園區 生醫路二段6-2號4樓之一
About us
Quark Biosciences, Inc was built on the vision of using the most innovative technologies to provide rapid, affordable precision healthcare solutions, in real-time, to patients around the globe. This is what gets us up in the morning and pushes us every day to find quicker, better, more accurate solutions in the fields of precision oncology and reproductive genetics.
QuarkBio has developed a groundbreaking new diagnostic solution, the NextAmp™ Analysis System, that combines the advantages and eliminates the disadvantages of existing technologies, addressing the challenges faced by the clinical testing field of precision medicine. The gene-chip-based diagnostic platform is designed to allow users to analyze up to 100 biomarkers in under two hours with minimal hands on time.
The system is built on the ideal of accessibility. In the context of QuarkBio, accessibility refers to:
• The affordable nature of the technology (for both patients, institutions, clinics)
• The intuitive functionality of the system (for institutions, clinics)
• The expedited, collaborative assay development process resulting from QuarkBio’s technology and know-how (for pharma, institutions, and, as an extension, patients)
QuarkBio’s team of eighty experts have committed hundreds of thousands of R&D hours over the past decade to redefine what high quality precision healthcare means and how it can be made accessible to the people who need it most. Our system is the high-powered result of this labor, enabling decentralized testing that generates on-the-spot results. Because at QuarkBio, we know that every minute matters, and every life is important.
Founded in 2012, Quark Biosciences has developed an innovative diagnostics platform for clinical testing, NextAmp™ Analysis System, which is built for ease of use, speed and decentralized distribution, while still being capable of performing highly complex multi-biomarker analysis. Coupled with our comprehensive genomic database, we are developing first-in-class tests in the precision oncology and fertility treatment markets.
Products
MIRA - The Next Generation microRNA-based Endometrial Receptivity Analysis
The next generation microRNA-based endometrial receptivity analysis
for IVF patients with a success rate of over 70%
- Providing a less invasive test by utilizing low sample amounts
- Utilizing novel biomarkers of a more stable nature, increasing the stability of the test while reducing the overall fail rate
- Simpler and faster operation time, shortening the turnaround time of the analysis and providing a speedier sample to data workflow
- Our quantitative amplification-based platform with higher reproducibility compared to NGS
- Easy-to-use, enabling decentralized labs to provide high quality service with consistency in numerous locations
MoDEL™ - The realtime EGFR mutation monitoring in NSCLC
A highly sensitive liquid biopsy for realtime EGFR mutation monitoring in NSCLC
for progression and drug resistance
-
Liquid Biopsy: Allowing detection of acquired drug resistance mutations in plasma
-
High sensitivity: Detection limit of 0.1% VAF (variant allele frequency), 10X more sensitive than conventional qPCR
-
Actionable mutations: Simultaneously analyzing classical sensitizing EGFR mutations and T790M in a timely manner
-
Real-time detection: Simple and efficient operation, providing results in less than one day
mirSCAN™ - A miRNA profiling platform covering 20+ disease types
A miRNA profiling platform covering 20+ disease types
for clinical researchers to discover and screen miRNA biomarkers faster and easier
- miDatabase: mirSCAN™ is supported by the most comprehensive miRNA database with annotated miRNA-gene-disease interactions.
- Superior sensitivity and specificity to distinguish subtle expression changes in clinical samples with lower quantity and quality, especially for liquid biopsy.
- AI-based analysis and algorithm for customization.